Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20608471 | 0.80 | CHRM4 (0.34) | CHRM4CYP1A2P2RX7 | |
| SCHEMBL20608461 | 0.79 | C5AR1 (0.39) | — | |
| SCHEMBL28886592 | 0.75 | ALDH1A1 (0.33) | — | |
| SCHEMBL29496236 | 0.72 | CHRM4 (0.35) | CHRM4CYP1A2 | |
| SCHEMBL12811481 | 0.71 | NOTUM (0.35) | CHRM4CYP1A2P2RX7 | |
| SCHEMBL17106485 | 0.71 | CYP1A2 (0.35) | CHRM4CYP1A2P2RX7 | |
| SCHEMBL19547099 | 0.71 | P2RX7 (0.42) | P2RX7 | |
| SCHEMBL29496297 | 0.70 | CHRM4 (0.63) | CHRM4CYP1A2 | |
| SCHEMBL3241010 | 0.70 | P2RX7 (0.34) | P2RX7 | |
| SCHEMBL23234134 | 0.70 | CYP1A2 (0.32) | CHRM4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-16 | — | — | US | disclosed |
| US-20190010122-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2019-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190010122-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | USP7, USP47, USP2 | CHRM4 4219/4885CYP1A2 893/4885P2RX7 4141/4885 |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | USP7, USP47, USP2 | CHRM4 4219/4885CYP1A2 893/4885P2RX7 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.